menu

Is It Bipolar Depression or MDD? Diagnostic Criteria

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Bipolar 1 and Bipolar 2 Depression – Timely Diagnosis and Effective Management in 2023 and Beyond

Is It Bipolar Depression or MDD? Diagnostic Criteria

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    Given the nature of symptom presentation of bipolar depression, patients can go undiagnosed for months, if not years. Moreover, these patients are at the risk of being misdiagnosed as having unipolar depression rather than bipolar depression, causing them to be at greater risk for being mismanaged. Effective management of patients with bipolar 1 and 2 depression is vital to enhance their quality of life and reduce functional disability. Health care providers (HCPs) need to be aware of the shortcomings of traditional monotherapy and adjunctive therapies; considering the ramifications associated with their side effects and efficacy, they have both adherence challenges and significant relapse rates. Additionally, HCPs must stay abreast of the pharmacological profiles of new and emerging agents. 

    This program discusses the timely diagnosis and effective management of bipolar 1 and 2 depression. Furthermore, clinicians will become familiar with algorithms and guidelines for effectively diagnosing and managing patients with bipolar depression. Through the timely diagnosis and effective management of patients with bipolar 1 and 2 depression, these patients spend less time unwell and their overall quality of life and functional outcomes are positively impacted. 

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including psychiatrists, nurse practitioners and physician assistants who specialize in treating psychiatric disorders, as well as other clinicians involved in the management of patients with bipolar 1 and 2 disorders.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Compare and contrast the clinical presentations of bipolar 1 depression, bipolar 2 depression, and unipolar depression to enable earlier recognition and an accurate diagnosis
    • Evaluate and implement evidence-based management strategies for bipolar 1 and bipolar 2 depression: mono vs. adjunctive therapies
    • Assess current treatment options and their clinical impact in the management of bipolar 1 and bipolar 2 depressions and incorporate them into a patient-centered evidence-based treatment plan
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.75 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Manpreet Kaur Singh, MD MS, faculty for this educational event, receives research grant from Johnson and Johnson and Allergan; receives royalties from Thrive Global and American Psychiatric Association Publishing; receives consulting fees from Sunovion, Skyland Trail, Johnson and Johnson, Alkermes, Neumora, AbbVie, Karuna Therapeutics Inc., and Boehringer-Ingelheim; and receives honoraria from American Academy of Child and Adolescent Psychiatry. 

    Joseph Frederic Goldberg, MD, faculty for this educational event, receives royalties from American Psychiatric Publishing and Cambridge University Press; receives consulting fees from Abbvie, Alkermes, Axsome, BioXcel, Intracellular Therapies, Neurelis, Neumora, Otsuka, Sage Pharmaceuticals, Sunovion, and Supernus. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Canan Schumann, PharmD/PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Intra-Cellular Therapies.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 3/31/2023 through 3/31/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule3 Mar 2024